beta-amyloid

Drugmakers Eisai and Biogen are putting the Food and Drug Administration to the test with a request to approve a second Alzheimer’s drug that works like aducanumab (Aduhelm), the new, yet controversial,...

Alzheimer’s Disease is increasingly being referred to as insulin resistance of the brain, or Type 3 diabetes, a research team says.

If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s...

Tauvid is the first drug to enable tau protein detection in adults who are being evaluated for Alzheimer’s, the agency reports.

A mechanism tied to disrupted sleep may underlie the link between beta amyloid deposits and cognitive impairment in seniors with cognitive disorders.

A “breakthrough” Alzheimer’s drug now looks much less promising after follow-up experiments failed to reproduce successful results, scientists recently announced. Non-standard use of...

Alzheimer’s researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.

Alzheimer’s researchers got a huge boost last week with the publication of a study showing that a rare genetic mutation prevents the buildup of beta amyloid in the brain.

A new test that measures amyloid levels in the spinal fluid of people with mild cognitive impairment could help physicians more accurately predict who will develop Alzheimer’s, a new study finds.

Nuclear medicine experts say positron emission tomography (PET) scans that detect beta amyloid plaques in the brain could make it to the marketplace within the next year. Beta-amyloid is a naturally occurring...